Biocon and Voluntis deal to transform insulin biosimilars personalized care through digital therapeutics

Biocon and Voluntis deal to transform insulin biosimilars personalized care through digital therapeutics: Biocon Biologics India, a subsidiary of Biocon, and digital therapeutics company Voluntis have recently announced a global collaboration agreement between Biocon Biologics’ subsidiary Biocon Sdn. Bhd.

VARINDIA- INDIA'S FRONTLINE IT MAGAZINE

Comments

Popular posts from this blog

N Chandrasekaran appointed chairman of Tata Sons

Visa buys NFT based CryptoPunk and paid $150,000 in Etherium

Prizm Payment Services changes its name to Hitachi Payment Services